A pharmacist was assigned for the period of 1 year. This pharmacist began with a 3-month phase-in period during which no interventions were done by the pharmacist, followed by 9 months of specific action on optimization protocols with the goal of achieving cost savings while maintaining best patient care. Training material for the pharmacist was developed and provided by the Canadian Blood Services Plasma Protein and Related Product Formulary Program team. The pharmacist worked in collaboration with CHEO staff on patient level data pertaining to the pharmacokinetics of individual treatment responses in an effort to optimise the dose and the treatment. McMaster’s WAPPS-Hemo served as the basis for therapeutic optimization. WAPPS-Hemo generates PK profiles that allow the pharmacist to tailor the treatment to the clotting factor’s actual profile, the targets of treatment, and the needs of the patient.⁷